Effectiveness of lurasidone in improving cognitive function in bipolar patients (who currently have no mood symptoms)

PURPOSE OF THIS STUDY:
This study is looking at changes in cognitive function in bipolar patients who are treated with 20 to 80mg/day of Lurasidone vs Placebo adjunctive therapy over a 6 week period.

WHO CAN PARTICIPATE?
> Males and females between 19-65 years of age
> Have a diagnosis of Bipolar Disorder
> Are clinically stable on current medication
> Not currently in a manic or depressed episode

WHAT IS INVOLVED?
The study involves a screening visit, baseline visit, clinical visits at Weeks 3 and 6, and 4 telephone calls at Week 1, 2, 4 and 2 weeks after last visit. Participants will complete neurocognitive (eg: memory, reasoning and attention) testing and give blood samples. Participants with cognitive impairment will be randomly allocated, to either receive lurasidone or placebo added to their current medications for 6 weeks.

CONTACT INFORMATION:
Jayasree Basivireddy, Clinical Research Coordinator
Phone: 604.822.3769
Email: jayasree.basivireddy@ubc.ca

To learn more about this study, visit vchri.ca/participate

STUDY TIME/DURATION
From July 2016 to December 31, 2019

STUDY LOCATION
Outpatient Clinic, Mood Disorders Centre, Djavad Mowafaghian Centre for Brain Health at UBC

PRINCIPAL INVESTIGATOR
Dr. Lakshmi N Yatham
Professor of Psychiatry, UBC
Regional Head, Department of Psychiatry
Regional Program Medical Director
Vancouver Coastal Health and Providence Health Care
Mental Health and Addictions